Microemulsion as Novel Drug Delivery for Fungal Eye Infection

Abstract

The cornea, orbit, and other ocular tissues may get infected by fungi. Ophthalmic mycoses, often known as ocular fungal infections, are a significant cause of morbidity and blindness. For fungus infections, a brand-new azole derivative has been authorized. New immunological techniques would also be beneficial in the future for enhancing patient outcomes. Treatment of ocular illnesses presents a significant barrier in terms of getting medications into the eyes using traditional drug delivery methods, such as solutions. The main barriers are those between blood and the eyes, between lachrymal fluid and the eyes, and between medication losses from the ocular surface brought on by lachrymal fluid secretion. To increase the bioavailability and lengthen the residence duration of medications administered topically to the eye, a variety of ocular drug delivery carriers have been developed. The microemulsion is created using the PHASE TITRATION METHOD. Due to the dual hydrophilic and lipophilic properties of microemulsions, the loaded medications can diffuse passively and become significantly partitioned in the varying lipophilic-hydrophilic ocular barrier. This abstract will provide details on the microemulsions used to treat fungal infections of the eyes.